Chemours Co (CC) Receives Consensus Recommendation of “Buy” from Analysts

Chemours Co (NYSE:CC) has been given a consensus rating of “Buy” by the eleven brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $58.00.

A number of equities analysts have issued reports on CC shares. Jefferies Group increased their price target on Chemours to $66.00 and gave the stock a “buy” rating in a report on Monday, December 4th. Zacks Investment Research upgraded Chemours from a “hold” rating to a “buy” rating and set a $57.00 price target on the stock in a report on Thursday, November 9th. UBS Group increased their price target on Chemours from $50.00 to $59.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Barclays increased their price target on Chemours from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Finally, Goldman Sachs Group cut Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price target on the stock. in a report on Wednesday, December 6th.

Shares of Chemours (NYSE CC) traded up $2.42 during mid-day trading on Friday, reaching $54.02. The company had a trading volume of 1,626,829 shares, compared to its average volume of 1,920,000. The company has a market capitalization of $9,980.00 and a PE ratio of 37.26. Chemours has a 1-year low of $24.17 and a 1-year high of $58.08. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63.

Chemours (NYSE:CC) last posted its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.11. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. Chemours had a return on equity of 116.80% and a net margin of 4.86%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.61 EPS. sell-side analysts predict that Chemours will post 3.65 earnings per share for the current year.

Chemours declared that its Board of Directors has authorized a share repurchase program on Friday, December 1st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the specialty chemicals company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 15th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.26%. This is a positive change from Chemours’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Wednesday, February 14th. Chemours’s dividend payout ratio is presently 8.28%.

In other news, insider E Bryan Snell sold 11,878 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $53.25, for a total transaction of $632,503.50. Following the transaction, the insider now directly owns 63,063 shares of the company’s stock, valued at $3,358,104.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christian W. Siemer sold 15,088 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $47.37, for a total value of $714,718.56. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Chemours by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock worth $600,289,000 after purchasing an additional 905,038 shares during the period. Renaissance Technologies LLC raised its position in shares of Chemours by 10.3% during the second quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock worth $126,736,000 after purchasing an additional 310,800 shares during the period. Bank of New York Mellon Corp raised its position in shares of Chemours by 7.9% during the third quarter. Bank of New York Mellon Corp now owns 2,371,909 shares of the specialty chemicals company’s stock worth $120,042,000 after purchasing an additional 173,523 shares during the period. JPMorgan Chase & Co. raised its position in Chemours by 11.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,201,287 shares of the specialty chemicals company’s stock valued at $110,969,000 after buying an additional 234,705 shares during the last quarter. Finally, Columbus Circle Investors raised its position in Chemours by 173.2% in the 3rd quarter. Columbus Circle Investors now owns 1,022,466 shares of the specialty chemicals company’s stock valued at $51,747,000 after buying an additional 648,200 shares during the last quarter. 74.36% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Chemours Co (CC) Receives Consensus Recommendation of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/20/chemours-co-cc-receives-consensus-recommendation-of-buy-from-analysts.html.

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply